Compare ADPT & NP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADPT | NP |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | 624 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.4B |
| IPO Year | 2019 | 2025 |
| Metric | ADPT | NP |
|---|---|---|
| Price | $28.51 | $29.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | $17.78 | ★ $28.17 |
| AVG Volume (30 Days) | ★ 1.8M | 347.4K |
| Earning Date | 05-05-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ 0.16 |
| Revenue | ★ $276,976,000.00 | N/A |
| Revenue This Year | $3.98 | $25.84 |
| Revenue Next Year | $22.72 | $15.80 |
| P/E Ratio | ★ N/A | $185.25 |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $12.00 | $14.78 |
| 52 Week High | $28.72 | $35.15 |
| Indicator | ADPT | NP |
|---|---|---|
| Relative Strength Index (RSI) | 73.65 | 33.32 |
| Support Level | $23.73 | $27.81 |
| Resistance Level | N/A | $34.60 |
| Average True Range (ATR) | 1.06 | 1.06 |
| MACD | 0.37 | -0.39 |
| Stochastic Oscillator | 97.40 | 2.14 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.